Investor Overview

Corporate Profile
Dermira is a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases.
Featured Reports
There are currently no items available.
Recent Newsmore >
DateTitle
09/20/16Dermira Licenses DRM04 to Maruho for Hyperhidrosis in Japan
Terms include $25 million upfront license payment to Dermira Maruho to fund all development and commercial costs for DRM04 in Japan MENLO PARK, Calif., Sept. 20, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced it has entered into an exclusive license agreement with Maruho Co., Ltd., a... 
09/12/16Dermira Acquires Option to License Exclusive Rights for up to Three Early-Stage Programs from Takeda
MENLO PARK, Calif., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that it has entered into an exclusive option and license agreement with Takeda Pharmaceutical Company Limited (TSE: 4502). Pursuant to the terms of the agreement, Dermira has acquired an option to license exclusive ... 
08/08/16Dermira Reports Second Quarter 2016 Financial Results and Provides Corporate Update
Reported Topline Results for Two Late-Stage Clinical Programs Raised Approximately $136 Million in Net Proceeds from Follow-on Public Offering Updates Guidance for Topline Phase 3 CIMZIA® (certolizumab pegol) Clinical Program Results MENLO PARK, Calif., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermat... 
06/13/16Dermira Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
MENLO PARK, Calif., June 13, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that it has closed its previously announced public offering of 5,175,000 shares of its common stock, including 675,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares of commo... 
Stock Quotemore >
DERM (Common Stock)
Exchange :NASDAQ GS (US Dollar)
Price :$34.38
Change (%) : Stock is Up 0.30 (0.88%)
Volume :65,825
Data as of 09/26/16 10:40 a.m. ET
Minimum 20 minutes delay
Eventsmore >
There are currently no events scheduled.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Dermira, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Minimum 20 minutes delayed